Diabetes & metabolism · 2025
Is Omnipod 5 cost effective for the management of type 1 diabetes among adults in France?
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Riveline Jean-Pierre, Hopley Colin, Olivieri Anamaria-Vera, Guigand Gabriel, Littlewood Melanie, Penfornis Alfred
Аннотация
AIM: -To compare long-term cost-effectiveness between the Omnipod® 5 Automated Insulin Delivery System and continuous subcutaneous insulin infusion + continuous glucose monitoring for type 1 diabetes among adults in France.
METHODS: - The analysis used the IQVIA Core Diabetes Model (v9.5) and considered both the French healthcare system and societal perspective. The study population and treatment effects were from the OP5-003 randomized controlled trial. Life-years, quality-adjusted life-years, incremental cost-effectiveness ratios and incremental cost-utility ratios, modeled over a 50-year horizon (base case), were analyzed. Sensitivity analyses were conducted to test treatment effects with different time horizons and discounting. Utility values were based on Omnipod 5 EuroQoL 3-Dimensions data and literature sources.
RESULTS: - In the base case, Omnipod 5 showed better clinical outcomes and lower diabetes-related complication rates than continuous subcutaneous insulin infusion + continuous glucose monitoring, gaining 0.373 life-years and 1.568 quality-adjusted life-years (incremental cost-utility ratio considering direct costs from a healthcare perspective = €791 per quality-adjusted life-year). With Omnipod 5, although direct healthcare costs were €1240 higher, there were savings from reduced complications, and total costs including societal productivity were €3071 lower. Sensitivity analyses confirmed lower total costs with Omnipod 5 across time horizons and discounting, and the direct cost-utility ratio was €2438 per quality-adjusted life-year when the treatment effect on glycosylated hemoglobin was halved.
CONCLUSION: - Considering the reported benefits on glycemic control and health-related quality of life, Omnipod 5 is a cost-effective alternative to continuous subcutaneous insulin infusion + continuous glucose monitoring for adults with type 1 diabetes in France.
METHODS: - The analysis used the IQVIA Core Diabetes Model (v9.5) and considered both the French healthcare system and societal perspective. The study population and treatment effects were from the OP5-003 randomized controlled trial. Life-years, quality-adjusted life-years, incremental cost-effectiveness ratios and incremental cost-utility ratios, modeled over a 50-year horizon (base case), were analyzed. Sensitivity analyses were conducted to test treatment effects with different time horizons and discounting. Utility values were based on Omnipod 5 EuroQoL 3-Dimensions data and literature sources.
RESULTS: - In the base case, Omnipod 5 showed better clinical outcomes and lower diabetes-related complication rates than continuous subcutaneous insulin infusion + continuous glucose monitoring, gaining 0.373 life-years and 1.568 quality-adjusted life-years (incremental cost-utility ratio considering direct costs from a healthcare perspective = €791 per quality-adjusted life-year). With Omnipod 5, although direct healthcare costs were €1240 higher, there were savings from reduced complications, and total costs including societal productivity were €3071 lower. Sensitivity analyses confirmed lower total costs with Omnipod 5 across time horizons and discounting, and the direct cost-utility ratio was €2438 per quality-adjusted life-year when the treatment effect on glycosylated hemoglobin was halved.
CONCLUSION: - Considering the reported benefits on glycemic control and health-related quality of life, Omnipod 5 is a cost-effective alternative to continuous subcutaneous insulin infusion + continuous glucose monitoring for adults with type 1 diabetes in France.